Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3465 SEK | -2.53% | +18.66% | -96.53% |
05-22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
05-16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
XBRANE BIOPHARMA AB | Other Biotechnology & Medical Research | -2.53% | +18.66% | -96.53% | -99.55% | -99.09% | 52.2M |
- Stock Market
- Equities
- XBRANE Stock
- Charts Xbrane Biopharma AB
- Relative Strength Chart